Statistical identifiability and the surrogate endpoint problem, with application to vaccine trials
From MaRDI portal
Publication:3076045
Recommendations
- Evaluating Candidate Principal Surrogate Endpoints
- Sensitivity analysis for evaluating principal surrogate endpoints relaxing the equal early clinical risk assumption
- Comparing biomarkers as principal surrogate endpoints
- Principal causal effect identification and surrogate end point evaluation by multiple trials
- A Bayesian approach to surrogacy assessment using principal stratification in clinical trials
Cites work
- scientific article; zbMATH DE number 1493045 (Why is no real title available?)
- Augmented Designs to Assess Immune Response in Vaccine Trials
- Causal Inference Without Counterfactuals
- Criteria for the Validation of Surrogate Endpoints in Randomized Experiments
- Evaluating Candidate Principal Surrogate Endpoints
- On meta-analytic assessment of surrogate outcomes
- Principal Stratification for Causal Inference With Extended Partial Compliance
- Principal stratification in causal inference
- Related Causal Frameworks for Surrogate Outcomes
- Simple relations between principal stratification and direct and indirect effects
- The evaluation of surrogate endpoints.
- The validation of surrogate endpoints in meta-analyses of randomized experiments
- Toward Causal Inference With Interference
Cited in
(18)- A unified evaluation of differential vaccine efficacy
- Design and estimation for evaluating principal surrogate markers in vaccine trials
- An information-theoretic approach for the evaluation of surrogate endpoints based on causal inference
- Assessing surrogate endpoints in vaccine trials with case-cohort sampling and the Cox model
- The 2-sample problem for failure rates depending on a continuous mark: an application to vaccine efficacy
- Surrogate measures and consistent surrogates
- Comparing biomarkers as principal surrogate endpoints
- A Bayesian approach to surrogacy assessment using principal stratification in clinical trials
- Incorporating baseline covariates to validate surrogate endpoints with a constant biomarker under control arm
- Translating questions to estimands in randomized clinical trials with intercurrent events
- Simultaneous inference of treatment effect modification by intermediate response endpoint principal strata with application to vaccine trials
- A multiple imputation approach for the evaluation of surrogate markers in the principal stratification causal inference framework
- Sensitivity analysis for evaluating principal surrogate endpoints relaxing the equal early clinical risk assumption
- A Bayesian approach to improved estimation of causal effect predictiveness for a principal surrogate endpoint
- Principal causal effect identification and surrogate end point evaluation by multiple trials
- Bayesian inference for the causal effect of mediation
- Surrogate marker assessment using mediation and instrumental variable analyses in a case-cohort design
- Evaluating principal surrogate markers in vaccine trials in the presence of multiphase sampling
This page was built for publication: Statistical identifiability and the surrogate endpoint problem, with application to vaccine trials
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3076045)
